grepcent public filings, reorganized for comparison

ZAVZPRET — FDA application NDA216386

Application NDA216386 · type NDA · FDA status: approved · original approval 2023-03-09

Listed sponsor: PFIZER · PFE company profile · exact_unique

Sponsor as listed in Drugs@FDA at retrieval (2026-08-07); FDA sponsor listings can lag ownership transfers.

FDA application facts

ProductFDA-listed trade nameActive ingredientDosage formRouteStrengthMarketing statusTE codeRLD
001ZAVZPRETZAVEGEPANT HYDROCHLORIDESPRAY, METEREDNASALEQ 10MG BASE/SPRAYPrescriptionnot listedYes

Product, form, strength, reference-drug and marketing-status fields: Drugs@FDA data files; TE and RLD fields: Orange Book data files. Retrieved 2026-08-07.

Orange Book patent and exclusivity listings

ListingProductDescriptive dateFlags/code
Patent 8481546001listed patent expiry date: 2034-06-26drug substance, drug product, U-3555
Exclusivity NCE001listed exclusivity date: 2028-03-09FDA code as listed
NDA216386 FDA listing dates. Source: Drugs@FDA and FDA Orange Book.NDA216386 FDA listing dates. Source: Drugs@FDA and FDA Orange Book.NDA216386 FDA listing datesDescriptive regulatory dates only; no relationship to revenue or future sales is stated or implied.Source: Drugs@FDA and FDA Orange Book.Listed dateDated listing marker0.001.002.002023-03-091.002028-03-091.002034-06-261.00

Patent and exclusivity dates are regulatory listings from the FDA Orange Book; no relationship to revenue or future sales is stated or implied.

Compound cross-links

Ingredient–compound links use FDA openFDA/GSRS identifiers and an exact lmmol InChIKey join. Ingredient names cannot create a link.

Related pages

Sponsor company · FDA-approved application index

Peer clusters: Large-cap biopharma

Sources: Drugs@FDA · Orange Book · openFDA application record. FDA data retrieved 2026-08-07.

Regulatory listing data as published by FDA; not medical or investment advice.